)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
TG Therapeutics
TG Therapeutics (TGTX) investor relations material
TG Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic focus and market overview
Focused on B-cell mediated diseases, primarily multiple sclerosis (MS), with Briumvi as the lead product.
Briumvi is approved globally, available in 16 countries, and has over 20,000 patients treated, mostly in the U.S.
Competes in the anti-CD20 market, which represents about $10 billion in sales and 50% of the MS dynamic market share.
Over 97% of top 200 MS centers use Briumvi, which holds about 20% dynamic share in the HCP-administered anti-CD20 segment.
Aims to become the number one prescribed anti-CD20 for relapsing MS based on dynamic market share.
Financial performance and guidance
Surpassed $1 billion in cumulative net sales, with $616 million in global revenue and $594 million in U.S. net revenue for the latest year.
Achieved 90% year-over-year growth and outperformed quarterly targets.
2026 global net revenue guidance is $875–$900 million, with $825–$850 million expected from the U.S.
Core operating expenses targeted at $350 million, with additional one-time costs for subcu Briumvi inventory and manufacturing.
Significant cash flow and EBITDA expected, with potential for increased share repurchases and accelerating profitability.
Product differentiation and commercial strategy
Briumvi offers a one-hour infusion every six months, with consistent efficacy and safety over six years.
Lacks breast cancer and colitis risks, and is glycoengineered for enhanced ADCC.
Priced as the lowest branded MS treatment, facilitating rapid payer coverage and broad access.
Won the VA contract, offering the lowest price for veterans in the U.S.
Customer service and experienced MS-focused team drive adoption and ease of onboarding.
How will SubQ BRIUMVI capture patient-admin share?
Prioritize non-MS BRIUMVI vs Azer-cel trials
Expected return on $100M one-time OpEx?
Detail the proprietary HCP targeting algorithm
Explain subcu BRIUMVI's non-cannibalizing growth
Azer-cel: What defines a 'win scenario' in PPMS?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next TG Therapeutics earnings date
Q4 202527 Feb, 2026
TG Therapeutics
Next TG Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; Umbralisib, an oral inhibitor of PI3K delta and CK1 epsilon for the treatment of CLL and follicular lymphoma; Cosibelimab, a human monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK over ibrutinib in in vitro kinase screening; TG-1801, a bispecific CD47/CD19 antibody generated by fusion technology platform across two distinct proteins each comprising single chain moieties from humanized IgG.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage